| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3624 | N-ethylglycine | Lidocaine metabolite, showing antinociceptive effects, inhibiting GlyT1-mediated glycine uptake |
|
| DCC3625 | N-ethylmaleimide | Modulator of the T1007 site, resulting in rapid activation of this transporter and potentiating KCC2 activity |
|
| DCC3626 | Neu321 | Ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth |
|
| DCC3627 | Neu-4854 | Novel potent Trypanosoma brucei Inhibitor |
|
| DCC3628 | Neu617 | Novel inhibitor of the growth of protozoan parasites, against T. brucei bloodstream proliferation |
|
| DCC3629 | Neu-730 | Novel inhibitor of TbrPDEB1, showing modest inhibition of T. brucei proliferation |
|
| DCC3630 | Neurodazole | Novel neurogenic inducer for converting pluripotent P19 cells into electrophysiologically active neurons |
|
| DCC3631 | Neuroprotectant-7 | Novel neuroprotectant for Alzheimers disease, showing significant neuroprotection and antioxidative properties, crossing the blood-brain barrier (BBB) |
|
| DCC3632 | Neurotensin(8-13) | The neurotensin active fragment, eliciting behavioral responses typical of clinically used antipsychotic drugs when administered directly to the brain |
|
| DCC3633 | Nexturastat A-crbn-12d | Novel potent HDAC6 degrader with promising antiproliferation activity in multiple myeloma (MM) cells |
|
| DCC3634 | Nfat-133 | Inhibitor of NFAT-mediated transcription, leading to the suppression of interleukin-2 expression and T cell proliferation, showing immunosuppressive, antidiabetic, and antitrypanosomal activities |
|
| DCC3635 | Nf-kappab Inhibitor-2 | First-in-class inhibitor of NF-κB signaling pathway by preventing the maturation of a rate-limiting multiprotein complex necessary for IKK activation |
|
| DCC3636 | N-formyl-met-phe | Neutrophil Dysfunction Test Peptide |
|
| DCC3637 | Nfu1827 | Novel inhibitor of human cytomegalovirus (HCMV) infection |
|
| DCC3638 | Ngd 98-2 | New generation, topology 2 selective orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist |
|
| DCC3639 | Ngd-8243 | Novel TRPV1 Antagonist |
|
| DCC3640 | Ngd9002 | New generation, topology 2 selective corticotropin releasing factor-1 (CRF-1) receptor antagonist |
|
| DCC3641 | Ngp1-01 | Brain-permeable dual blocker of neuronal voltage- and ligand-operated calcium channels, acting as chemosensitizer and circumvent the resistance of the plasmodia parasite against chloroquine (CQ) by inhibiting the p-glycoprotein efflux pump and enabling th |
|
| DCC3642 | Nh2-bodipy | Novel cell-permeant probe for the super-resolution imaging of the endoplasmic reticulum in live cells |
|
| DCC3643 | Nh2-nplh2 | Novel luciferin analog, enabling both sensitive and highly resolved imaging in vivo |
|
| DCC3644 | Nh2-uamc1110 | UAMC1110 Conjugate Linker |
|
| DCC3645 | Nhi-1j | Selective Inhibitor of Human Lactate Dehydrogenase Isoform A (LDH-A) |
|
| DCC3646 | Nicodicosapent | Novel inhibitor of the sterol regulatory element binding protein (SREBP) |
|
| DCC3647 | Nicofibrate | Antilipidemic agent |
|
| DCC3648 | Nifrofam | Novel fluorescent probe for imaging α4β2* nAChRs |
|
| DCC3649 | Nik-21273 | Potent and selective NOP receptor antagonist |
|
| DCC3650 | Nim811 | Cyclophilin inhibitor, showing reduction in interleukin-2 expression and reduction in CNS inflammatory infiltrates, inhibiting HCoV-229E replication |
|
| DCC3651 | Ningetinib Tosylate | Novel potent tyrosine kinase inhibitor (TKI), targeting c-Met, VEGFR2 and Axl |
|
| DCC3652 | Niraparib R-enantiomer | Novel potent PARP1 inhibitor |
|
| DCC3653 | Nir-bg2 | Novel self-immobilizing near-infrared (NIR) fluorogenic probe that can be activated by senescence-associated ß-galactosidase (SA-ß-Gal), the most widely used senescence marker |
|
